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Abstract
It is often said that it takes 17 years to move medical research from bench to bedside. In a coronavirus disease (COVID-
19) world, such time-lags feel intolerable. In these extraordinary circumstances could years be made into months? If so,
could those lessons be used to accelerate medical research when the crisis eases?
To measure time-lags in health and biomedical research as well as to identify ways of reducing them, we developed
and published (in 2015) a matrix consisting of overlapping tracks (or stages/phases) in the translation from discovery
research to developed products, policies and practice. The matrix aids analysis by highlighting the time and actions
required to develop research (and its translation) both (1) along each track and (2) from one track to another, e.g. from
the discovery track to the research-in-humans track. We noted four main approaches to reducing time-lags, namely
increasing resources, working in parallel, starting or working at risk, and improving processes.
Examining these approaches alongside the matrix helps interpret the enormous global effort to develop a vaccine for
the 2019 novel coronavirus SARS-CoV-2, the causative agent of COVID-19. Rapid progress in the discovery/basic and
human research tracks is being made through a combination of large-scale funding, work being conducted in parallel
(between different teams globally and through working in overlapping tracks), working at greater (but proportionate)
risk to safety than usual, and adopting various new processes. The overlapping work of some of the teams involves
continuing animal research whilst entering vaccine candidates into Phase I trials alongside planning their Phase II trials.
The additional funding available helps to reduce some of the usual financial risks in moving so quickly. Going forward
through the increasingly large human trials for safety, dosage and efficacy, it will be vital to overlap work in parallel in
the often challenging public policy and clinical tracks. Thus, regulatory and reimbursement bodies are beginning and
preparing rapid action to pull vaccines proving to be safe and effective through to extraordinarily rapid application to
the general population. Monitoring the development of a COVID-19 vaccine using the matrix (modified as necessary)
could help identify which of the approaches speeding development and deployment could be usefully applied more
widely in the future.
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Understanding the time-lags between research
and its application
The idea that it takes, on average, 17 years from starting
research to its translation into products, policies and
practice has gained considerable traction in recent years
since the review by Morris, Wooding and Grant asked:
“The answer is 17 years, what is the question?” [1]. How-
ever, with coronavirus disease (COVID-19) causing so
many excess deaths and effectively shutting down many
usual social and economic activities, a 17-year wait for a
vaccine feels intolerable. So how could the lag between
bench and bedside be reduced to, say, just 17 months (or
even less)? In an extreme crisis, extraordinary things can
be achieved, yet there are reasons for the 17-year time-
lag – so what has changed?
The 17-year time-lag quoted by Morris et al. was de-
duced from a review of 23 papers; however, as the au-
thors concluded, different studies were “[u]sing different
endpoints, different domains and different approaches”
[1]. The authors identified a group of studies that exam-
ined a broad range of interventions from the start of re-
search to some aspect of adoption in clinical practice
[2–5]. These studies coalesced around an average figure
of 17 years, which has since been commonly cited in the
policy debate and literature [6–8].
Buxton et al.’s study of the returns to United Kingdom
public and charitably funded cardiovascular disease re-
search [2] was one of the papers included in Morris
et al.’s review [1]. Despite the 17-year time-lag estimated
in their study, Buxton et al. [2] calculated that there was
nevertheless a high rate of return on medical research,
which included both the value of improved health and
the value to the economy. (Subsequent to the publica-
tion of Morris et al.’s review [1], Buxton et al. found
similar timelines in their further studies of the returns to
research on musculoskeletal disease and cancer [8, 9].
The rate of return, however, would have been even
higher if the time-lags had been shorter. This highlighted
the importance of understanding time-lags and how they
could be reduced. Subsequently, the United Kingdom’s
Medical Research Council funded the authors of this
Commentary, along with other authors, to explore this
issue. In 2015, we published our findings including a con-
ceptual matrix that informed our analysis (Fig. 1) [10].
That matrix, along with the approaches we identified for
reducing time-lags, provides a framework to examine the
Fig. 1 Conceptual matrix for measuring and understanding time-lags Source: Hanney et al. [10]
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current race to develop a COVID-19 vaccine. Such ana-
lysis of the accelerated development, and its opportunity
costs, could provide lessons both for accelerating the de-
velopment of future therapies through to routine health-
care use and enhancing the approach used in future
analyses of time-lags.
In the time-lags study, we developed an approach to
present data on multiple tracks (or stages or phases) in
the translation of research into healthcare improvements
that went beyond a simple linear representation and
recognised the importance of incorporating scope for
overlaps. We noted the rich literature on the challenges
faced in the diffusion of innovations [11], but focused on
exploring the time-lags in the whole spectrum between
early research and the eventual translation into health
gains [10]. Our starting point was the process marker
model developed by Trochim et al., which helpfully identi-
fied a series of “operationally definable” markers, or mile-
stones, in the “research –practice translation continuum”
[12]. We built on this considering each of the major steps
in the translation process from early research through to
adoption in the healthcare system. We built these markers
into a matrix and tested the validity of our approach by
identifying the markers in data from our previous analysis
of the eventual healthcare impact in diverse countries
resulting from a stream of animal and human research on
the use of corticosteroids for the prevention of respiratory
distress syndrome (RDS) [13]. This initial test showed
promise and illustrated the value of featuring overlaps –
in the RDS case, there was some adoption in clinical prac-
tice well before further activity had to return to the na-
tional policy and guidelines track to encourage wider
adoption at an appropriate level in clinical practice.
The matrix consists of four main tracks, two of which
contain the research (discovery research, which we defined
very broadly, and human research/research review) and
two of which cover the public policy and clinical practice
developments. The two middle tracks each consist of a
number of separate sub-tracks. The model facilitates the
analysis of time-lags by allowing consideration of two
linked issues: the time and actions required to move re-
search (and its translation) (1) along any particular track
and (2) from one track to another at the cross-over points
between tracks. We conducted a series of seven case stud-
ies to test and refine the matrix. They covered diverse
types of research, including examples of the development
of drugs, screening, cognitive behavioural therapy and
early intervention, in the two fields of cardiovascular dis-
ease and mental health [10]. These cases (along with the
RDS example) highlighted the following:
 A time lapse between discovery and routine use is
inevitable and desirable to ensure the safety, efficacy
and cost-effectiveness of new interventions.
 Most timelines include some examples of where there
had been considerable delays in the continuum as well
as some examples of quite rapid movement from one
track to the next (e.g. the 2008 policy to introduce
national screening for abdominal aortic aneurysms in
England was rapidly and comprehensively
implemented in the clinical practice track to cover
300,000 people annually) [10].
 Using overlapping tracks facilitates the exploration
of the time-lags, including in the later stages of the
matrix involving public policy and widespread adop-
tion in clinical practice – areas which the literature
also shows are often subject to considerable delays
[10, 11, 13, 14].
Our 2015 study also included an update of the Morris
et al. review [1] and found a similar picture with identi-
fied papers not measuring time-lags in a comparable
way, even though, in this instance, they predominantly
had a pharmaceutical focus [10]. In these studies, there
was more homogeneity about the end point than the
start point for measuring but, because that common end
point was the licensing/approval process, it meant that
they were stopping the time-lag measurements much
earlier than shown in our matrix.
Approaches to reducing time-lags from early research to
its translation
So, how might it be feasible to reduce 17 years to per-
haps 17 months, or less? In diverse countries, there has
been detailed analysis of various mechanisms for redu-
cing elements of the time-lags, particularly ones focusing
on parts of the continuum such as the track from evi-
dence to practice and policy [14] and the regulatory ap-
proval and reimbursement tracks [15]. Below, however,
we draw primarily on analysis in our own 2015 article
[10] (and our dissemination of it [16]) to outline four
overlapping approaches or strategies. In the subsequent
section, we apply the approaches alongside the tracks in
the matrix to explore the extraordinary efforts being
made to reduce the elapsed time in the development of
a vaccine for the 2019 novel coronavirus SARS-CoV-2,
the causative agent of COVID-19.
Increasing resources
The case studies identified various situations in which
translation would have been speeded up by more re-
sources being available at key points in various tracks,
including the resources to train additional cognitive be-
havioural therapists, which were eventually made avail-
able [10]. While very large sums are spent globally on
medical research each year, the development of any spe-
cific intervention might be delayed because of insuffi-
cient resources or wastage. When detailed studies are
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conducted of the development of major new successful
interventions along various tracks, it sometimes appears
with hindsight that there were inexplicable delays at cru-
cial points while decisions were made about whether to
pursue the research. In reality, however, with so many
new interventions always in the pipeline, at various
points, queues develop for decisions, be it about funding
of the next stage or track, or ethics approval, among
others [10]. Queues could often be reduced by applying
greater resources, which would also inevitably help facili-
tate some of the additional approaches below; however,
increasing resources means, by definition, increased cost.
Working in parallel
A major advantage of creating the overlapping tracks in
the matrix is that it promotes the idea that actions are
taken in parallel at certain times. We reported an example
of this happening with screening trials at the equivalent of
the Phase II and Phase III trials [10]. When this happens,
it can increase efficiency and reduce the time taken overall
albeit likely at the cost of increasing risks – although it did
not in this specific example. In addition to parallel work in
different tracks of the matrix, there might also be coordi-
nated parallel work by different research teams collaborat-
ing to speed up progress.
Starting or working at risk
The two key risks are safety risks and financial risks.
Safety risks in the research processes might entail work-
ing in parallel in the next track. Safety risks might also
involve liaison with the regulator about how far the
Phase I-III trials have to go before the regulator will give
approval for use. We identified the literature showing
that drugs for HIV/AIDS had the shortest Phase III and
overall times; sponsors were allowed to file New Drug
Applications (NDAs) to the United States regulators
without completing large-scale human trials [17]. We
noted that “the process seems to have been speeded up by
the adoption by the regulator of a different benefit-risk
profile in response to the particular circumstances posed
by HIV/AIDS and the demands of patients” [10]. In an
additional file linked to our 2015 article, we also de-
scribed the various steps that regulatory bodies, such as
the Food and Drugs Administration in the United States,
can take to speed up approval of a medication for ser-
ious diseases, especially where it is the first available
treatment [10]. These include more frequent meetings
and correspondence with the developers to discuss the
collection of appropriate data and trial design. Further-
more, there can be a rolling review process where the
parts of an NDA that are ready can be submitted instead
of the usual procedure of waiting until the entire NDA
is ready [10]. A framework for thinking about ways of
accelerating this track was developed by one of the
authors in work subsequent to our time-lags study [15].
The financial risks to the organisations developing drugs
arise because trials in later phases of the human research
track are larger and more expensive than the earlier
ones. Furthermore, many candidate interventions in
early trials are not successful [18]. For both these
reasons pharmaceutical companies and other research
organisations prefer to wait and confirm progress at one
stage before moving onto the next [19]. However, in a
crisis, companies might be willing to take more risk (and
this is an example where the provision of additional re-
sources could matter – see below).
Improving processes
This can apply along tracks as well as between tracks
and an accumulation of small improvements to specific
items, such as accelerated ethics and peer review, could
add up to significant time reductions and a consequent
improvement in efficiency in getting new interventions
into use [10, 16]. In one case study, we noted that more
resources would allow bodies making reimbursement
decisions to more often adopt the speeded up process
that the National Institute for Health and Care Excel-
lence (NICE; England and Wales) used in the excep-
tional circumstances of a drug’s Phase IV trial being
stopped early following significantly higher mortality
rates in the trial’s other arm [10].
Developing a COVID-19 vaccine in record time
None of the seven case studies in our study examined
vaccine development and there are some features of that
field that are likely to contribute to faster translation
from research to application than in other fields. For ex-
ample, in the past, the vaccine field has had relatively
low market margins and is often seen as commercially
unattractive [20–22]. As a consequence, quite a lot of
the relevant research is conducted in universities, mean-
ing that there are many ideas around the proof-of-
concept stage that are ready to go – they provide a fer-
tile area for integration once financial or other incentives
appear. Nevertheless, the development of vaccines is still
sometimes reported to take, on average, over 10 years
and there is often an attrition rate for vaccine candidates
of about 90% or higher as they go through the various
tracks [18, 23, 24].
Despite those average figures, there are at least three
particular features in the context of the development of
a COVID-19 vaccine that are particularly important and
play across various tracks, even if they are not likely to
appear in many, or any, other situations. First, there is
the intense and overwhelming nature of the COVID-19
crisis that is engulfing the globe and making it the top
priority for action everywhere – meaning many priori-
tisation decisions are a given. Second, the widespread
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lockdowns and social distancing are also restricting re-
search activities generally, with many laboratories not
functioning apart from those conducting work linked to
COVID-19 [22]. This highly unusual situation might
mean that, in the short-term at least, concentrating re-
sources on one area does not have the usual opportunity
costs of depriving other areas of resources – because
they have generally been put on hold. It is therefore pos-
sible that the queues for research resources will be much
less in evidence. (However, the more usual pattern could
rapidly reinsert itself as the lockdowns ease.)
Third, SARS-CoV-2 is the latest of a series of corona-
viruses for which research teams have been seeking vac-
cines [18, 21]. Therefore, various tools, such as vaccine
platforms that had already been developed or new ones
that were in development, can be integrated in the
search for a vaccine against the new disease. Linked to
this, several non-market mechanisms were developed to
make better preparation for a future epidemic, including
the Coalition for Epidemic Preparedness Innovations
(CEPI) based in Oslo, Norway. Established in 2017, it re-
ceives funding from governments and donors such as
the Bill & Melinda Gates Foundation and the Wellcome
Trust [21]. In addition to funding development of 17
vaccines against five priority pathogens, CEPI also
“funded programs for unknown emergent pathogens –
programs for ‘Disease X’. ‘Disease X’ now has a name:
COVID-19” [21].
The four approaches above for speeding things up can
now be considered, alongside the matrix in Fig. 1, to
analyse how things are currently being accelerated. This
draws on what has already been written about the extra-
ordinary efforts being made by a global community of
scientists, healthcare industries and coordinating organi-
sations such as WHO and CEPI since a Chinese team
published the genetic sequence of SARS-CoV-2 on 11
January 2020 [23]. Working with WHO, CEPI has devel-
oped and is “continuously maintaining an overview of
the global landscape of COVID-19 vaccine development”
[23]. CEPI has also estimated that many billions of dol-
lars will be needed for the successful rapid development
and manufacture of one or more vaccines [25].
When considering speeding up progress on developing
and delivering a COVID-19 vaccine against in each of
the four groups of tracks in Fig. 1, it is immediately obvi-
ous that the concept of overlapping tracks is hugely im-
portant and facilitates the idea of working in parallel on
various items. Additionally, some of the drivers of the
increased speed are the overlapping action in the regula-
tory and reimbursement tracks towards the top of the
matrix, which can potentially play a role in pulling devel-
opments through more rapidly from the lower tracks.
The CEPI team have developed a paradigm specifically
for a pandemic, which they contrast with a more linear
traditional paradigm for vaccine development [19]. As
with our Fig. 1, the key feature of this are the phases that
overlap; additionally, it includes the development of
manufacturing capacity in the overlapping phases, which
will be crucial for the rapid mass production of the vac-
cines. We had not included manufacturing capacity in
our matrix as investing in sufficient capacity is generally
not the limiting factor in conventional development of
new medicines. Consequently, manufacturing capacity
did not arise as a delaying issue in our case studies – al-
though there was possibly a somewhat comparable situ-
ation with the lack of capacity in the form of trained
cognitive behavioural therapists, until resources were
found for additional training. However, given the scale
of manufacture likely to be necessary for COVID-19 vac-
cines and the hoped-for considerably shortened time-
scale, it is being highlighted as an issue in current
discussions [25]. The analysis below linked to our matrix
throws light on how events are unfolding in a timescale
that is much more rapid than previously seen.
Discovery research track
Partly through the large-scale funding provided through
CEPI and others, some teams are reporting extremely
rapid progress with basic preclinical/animal research; for
example, a press release from Inovio, a United States
company, on 6 April 2020 marking the launch of its
Phase I clinical trial, stated the following: “Preclinical
data, which have been shared with global regulatory au-
thorities and submitted as part of the IND [Investiga-
tional New Drug] [application], have shown promising
immune response results across multiple animal models”
[26]. The company went on to say that additional pre-
clinical studies “will continue in parallel with the Phase
1 clinical trial”. One of the keys to rapid progress, in this
case with a DNA vaccine and in other cases, such as the
University of Oxford’s Jenner Institute in the United
Kingdom, with a vector vaccine, is that the teams had
already been working on a vaccine for MERS-CoV, an-
other coronavirus that is the causative agent for Middle
East Respiratory Syndrome (MERS) [26, 27]. Gilbert ex-
plained how her team at the Jenner Institute had con-
ducted research using improved research processes prior
to the pandemic to create a new vector vaccine platform
and had “started thinking about an appropriate response
to Disease X; how could we mobilise and focus our re-
sources to go more quickly than we had ever gone before.
And then Disease X arrived” [27]. Gilbert is aiming to
have a vaccine ready for use in Autumn 2020, a shorter
timescale than any other team seems to have suggested;
however, in terms of identifying the starting point of the
relevant research, which is always problematic [10], her
discovery research stretches back well before January
2020 [27]. A major new feature assisting the more rapid
Hanney et al. Health Research Policy and Systems           (2020) 18:61 Page 5 of 10
development of a vaccine now is the unprecedented level
of global cooperation within the scientific community
and with other relevant bodies, with, for example, scien-
tists reporting important findings on conference calls
organised by WHO rather than using time to write and
publish academic papers [21, 22]. Some of the animal
trials for both Inovio and the Jenner Institute are being
conducted by a laboratory of Australia’s Commonwealth
Scientific and Industrial Research Organisation. It
pointed out that “Normally it takes about one-to-two
years to get to this point and we’ve in fact shortened that
to a period of a couple of months” [28]. Preclinical testing
for the Jenner Institute has also been conducted in the
United Kingdom and United States, with promising re-
sults reported [29].
Improved processes also have a role in reducing devel-
opment time during the pandemic [21, 27]. In particular,
novel platforms are being used, with those based on
DNA or mRNA offering “great flexibility in terms of
antigen manipulation and potential for speed” [23]. A
partnership between another company, Moderna, and
the United States National Institute of Allergy and Infec-
tious Diseases (NIAID) started clinical testing of Moder-
na’s mRNA-based vaccine just 2 months after the
announcement of the genetic sequence but ini-
tially skipped one of the stages of animal testing [28].
While the mRNA-based platform for delivering vaccines
had been shown to be safe in humans, this COVID-19
vaccine had not [30], and “mRNA-1273 faces numerous
challenges in clinical development and manufacture be-
fore it has the possibility of being made available for glo-
bal immunization” [21]. Animal studies are usually a
vital first step, required for regulatory approval.
Human research and research review tracks
Phase I, II and III – first-in-human/safety, design/dosage,
efficacy
We consider these three phases as one group because
different approaches use somewhat different terminology
but still cover the same essential items. The CEPI ana-
lysis of the COVID-19 vaccine development landscape
published on 9 April 2020 reported that, of the 78 iden-
tified vaccine candidates confirmed as active, five were
in Phase I trials – the studies by Moderna and Inovio
described above, plus three Chinese studies [23]. Follow-
ing links in that paper reveals that all five anticipate
many months of research just for Phase I, although, as
reported in late April 2020, CanSino, a Chinese company
developing a vector vaccine [23], was the first to move
into a, presumably overlapping, Phase II study [24]. In a
press release on 30 April 2020, Inovio referred to poten-
tially advancing “to Phase 2/3 efficacy trials this summer”
[31]. Vital considerations in how far the candidate vac-
cines will move through the trial phases and the extent
of overlap will be considerations of safety and financial
risk. There are suggestions that some of the usual safety
procedures that could constrain progress during the tri-
als might be relaxed, with the NIAID, which is conduct-
ing the Phase I trial of Moderna’s mRNA vaccine,
reportedly arguing that “the risk of delaying the advance-
ment of vaccines is much higher than the risk of causing
illness in healthy volunteers” [30]. Moderna’s Phase I
trial initially enrolled 45 volunteers in the original three
dose cohorts, but later added six more cohorts [32]. On
27 April 2020, Moderna, with funding from the United
States Government’s Biomedical Advanced Research and
Development Authority (BARDA), submitted an Investi-
gational New Drug application to the Food and Drugs
Administration for “Phase 2 and late stage studies of
mRNA-1273 if supported by safety data from the Phase 1
study” and reported, on 1 May 2020, that it had received
initial feedback on the design of a 600-participant Phase
II trial, which it expected to start it in the second quarter
of 2020, with a 12-month follow-up [32]. This again il-
lustrates that regular liaison with the regulatory bodies is
likely to be essential during the research as new plat-
forms, new approaches and the immense urgency of the
situation all come together.
Gilbert described the importance of work at the Jenner
Institute running in parallel, funded by grants from vari-
ous sources and, while the preclinical research was un-
derway, she received ethical approval for the clinical trial
and conditional approval from the United Kingdom’s
regulatory authority to screen volunteers for trial enrol-
ment [27]. Furthermore, in April 2020, drawing on the
safety data from their previous trials of similar vaccines,
the Jenner Institute team were able to discuss with the
United Kingdom regulators the basis on which they
could start a combined Phase II/Phase III trial with an-
other 5000 participants [29] in addition to the 1102 in
the Phase I trial [24]. Some of the grants received by this
team also helped fund initial scaling up of vaccine pro-
duction using facilities in the United Kingdom and else-
where [27, 29]. The size and speed of the human trials
that the Jenner Institute is progressing reflect the confi-
dence gained from its prior research on other vaccines
and animal testing of its COVID-19 vaccine in various
models [27–29]. The apparently smaller and more grad-
ual Phase I trial by Moderna, and plans for its Phase II
trial, perhaps reflect the greater caution that is necessary
in its human trials (despite its previous work on similar
vaccines) as it avoided some of the animal trials prior to
being the first to conduct human trials.
Mitigating the financial risk to running phases in par-
allel is the additional funding being devoted to develop-
ing a vaccine, with CEPI, among others, playing a key
coordinating role in distributing donations. Also acceler-
ating progress is that any decisions about a COVID-19
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vaccine are going straight to the head of any queue for
decisions about, for example, resources or ethics ap-
proval. In terms of encouraging the maximum participa-
tion by commercial enterprises, some of the debates
being conducted in the ‘Reimbursement/financial sup-
port’ track could be extremely important in providing
incentives.
Effectiveness/post-launch research track and research
review and synthesis on effectiveness and safety track
These top two tracks of human research (Fig. 1) are usu-
ally important, including when, as often happens, new
interventions are developed in an area where there are
already existing interventions; this may be in order to
gather cost-effectiveness data to inform policy on reim-
bursement decisions. With the development of a vaccine
for COVID-19, as there are no existing alternatives, it is
extremely unlikely that such steps would be necessary
before regulatory approval and reimbursement decisions
about the first approved vaccine. However, they might
subsequently become very important if additional vac-
cines are developed and approved.
Clinical and health service track and public policy and
development track
Regulatory approval/first non-research use in patients and
monitoring
This essential step has to occur after the safety, dosage
and efficacy trials and, while there are calls for it to be
completed as rapidly as possible, there are also pleas
“not to cut corners” [30]. Jiang points out that vaccines
for other major diseases “have a long history of safe use
and were developed in line with requirements of regula-
tory agencies”. He has worked to develop vaccines for
various coronaviruses since 2003 and describes some of
the potential dangers [30]. Nevertheless, there is clearly
considerable scope in the current situation for any vac-
cine for COVID-19 to jump, or even avoid entirely, the
queues that often exist in the work of regulatory bodies.
Various teams, including the Jenner Institute and Inovio,
are talking about their candidate vaccine potentially be-
ing ready in later 2020 or early 2021. Some suggest it
will first be made available using the speeded up or
emergency use procedures that, as discussed above, the
regulatory bodies are able to use in exceptional circum-
stances [23, 26, 33, 34]. A member of the Jenner Insti-
tute team referred to the critical importance of the
principle of transparent informed consent [33]. Regula-
tory authorities are already beginning to work in parallel
with the organisations developing candidate vaccines, so
that they are fully aware of how the trials are progressing
and might indicate the extent of the evidence that would
be necessary for approval in this crisis situation, as noted
previously with HIV/AIDS. Regulatory authorities will
have crucial decisions to make in the coming months
about how far they are willing to take greater risks about
safety in relation to vaccine use as well as what greater
risks might be taken with the health of volunteers in the
trials (see above).
National policy announcement/guidelines advice
It is highly likely that such decisions on using the vac-
cine would already be in place when the vaccine was
ready for use. Thus, whereas there can often be long de-
lays before action is taken on this track to promote the
use of an intervention, in this instance, such delays are
extremely unlikely.
Reimbursement/financial support
It is to be expected that the vaccine manufacturers and
healthcare systems will have worked out these arrange-
ments before any vaccine receives regulatory approval.
Thus, again, this sometimes lengthy process should be un-
characteristically unlikely to cause delays on this occasion.
This is another clear example of where there are likely to
be overlaps and work in parallel on many tracks. Various
funding proposals are emerging and it is widely assumed
that such will be the demand for a vaccine that more than
one will go into mass production [34, 35]. Overlapping ap-
proaches being advocated and implemented include carry-
ing out more research and development (R&D) through
the public sector but bringing in the private sector primar-
ily for manufacture and distribution and adopting ‘ad-
vance market commitments’ to incentivise private R&D;
the first approach is being taken by the Jenner Institute. In
the first few months, funding for the Jenner Institute’s
COVID-19 research has come from various public and
charitable sources, including the donations channelled
through CEPI and direct funding from the United King-
dom public funders of health research [23, 27]. At the end
of April 2020, the Jenner Institute partnered with the
British–Swedish company AstraZeneca, with support
from the British Government, for the development, manu-
facture and large-scale distribution of the vaccine on a
not-for-profit basis, with only the costs of production and
distribution being covered [35]. This approach is not com-
pletely novel in the vaccine space but is the largest of its
kind to date – it will be interesting to see if such ap-
proaches spread to other areas of healthcare. The
Moderna vaccine candidate also shows aspects of this ex-
tension of the public sector role with some of Moderna’s
BARDA support being used to develop manufacturing
capacity in the United States, through collaboration with
Lonza US (part of Swiss-based Lonza), which will comple-
ment Moderna’s existing more limited United States
manufacturing capacity. It is aiming to start production
prior to the completion of trials and scaling global produc-
tion to a billion doses per year [32].
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Related to the second approach of ‘advance market
commitments’, Silverman et al. describe how, in terms of
increasing the speed of development of vaccines, the
supply-side investments in R&D are the pressing issues
but that getting the demand-side right is also important
[36]. In contrast to the Jenner Institute model, they
claim that if society wishes industry to invest up-front in
the risky, high-cost business of vaccine development, it
might need “to offer the promise of a predictable market
for an effective vaccine that offers both access for all and
a reasonable return on investment – de-risking market
(commercial) uncertainty while still expecting companies
to absorb the scientific risk that their products will fail”.
They also illustrate the considerable commercial risks
that companies have faced when developing vaccines, in-
cluding against previous coronaviruses. In that context,
they propose that the ‘market-driven value-based ad-
vanced commitment’ is the best option as it “differenti-
ates price according to efficacy, so incentivizing
development and use of vaccines with higher rates of dis-
ease prevention”, but could also ensure vaccines were
available at manufacturing cost for low-income countries
[36]. This illustrates how, in this extreme situation, en-
suring a credible promise of sufficient resources being
available is likely to play an important role across the
various tracks in the development of a vaccine.
Clinical practice track
Given the enormous health and economic burden being
caused by COVID-19, it is reasonable to assume that, in
contrast to what often happens [11, 14], there will be no
delay from healthcare professionals in starting to give
the vaccine to populations as soon as regulatory ap-
proval is secured and manufacturing capacity has geared
up. CEPI has called for “funding to support global
COVID-19 vaccine development efforts guided by three
imperatives: speed, manufacture and deployment at
scale, and global access” [23]. Questions about equity in
deciding who receives the vaccines, and who receives
them first, are of huge importance, but they are beyond
the scope of this Commentary, which focuses on the
time between starting research and the application of
the intervention as a standard procedure within clinical
practice in at least some countries. However, as noted
above, some approaches can incentivise innovation while
also encouraging a more equitable distribution than
might otherwise occur.
Lessons for speeding up future research
Currently, it appears as though progress through the
tracks is likely to be rapid and several themes appear to
be emerging. First, in every track, we can already see, or
expect, the rapid progress that we saw examples of scat-
tered among the various case studies described above
but never saw concentrated in one case. Second, we can
already see examples of additional acceleration activities
speeding up processes in various tracks. The full lessons
from the development of one or more vaccines against
COVID-19 will, however, only become apparent after
successful vaccine application globally to combat SARS-
CoV-2. In the meantime, the analysis here should help
to identify factors to monitor as it is apparent that the
rapid speed on this occasion is likely to be caused by a
combination of many factors. These might include some
changes, such as improved research processes, which
may be valuable in future for other streams of biomed-
ical research. Our analysis could feed into debates that
are already beginning about how the pandemic might in-
fluence research systems in the future, with an emphasis
on reducing red tape in applications and a greater focus
on societal impact [37].
At the other end of the spectrum, there will be
changes that cannot be replicated, at least in such an ex-
treme form. These include the significant increase and
concentration of resources resulting from both the extra
financing being mobilised because of the intense urgency
of the crisis and the consensus on prioritisation of re-
sources in terms of avoiding the queues for attention
from decision-makers in the research and public policy
systems. In between, there are many factors where the
possibility of applying improvements in future will need
careful scrutiny and perhaps promotion. These might in-
clude factors such as working at increased risk and
working in parallel and cooperatively.
Gilbert is clear that cooperation is vital for tackling the
current crisis, “Work is continuing at a very fast pace,
and I am in no doubt that we will see an unprecedented
spirit of collaboration and cooperation, convened by
WHO, as we move towards a shared global goal of
COVID-19 prevention through vaccination” [27]. The co-
operation is even seeing old rivals, such as GlaxoS-
mithKline from the United Kingdom and Sanofi from
France, forming a partnership to speed up progress by
combining their complementary strengths, as part of
wider cooperation in which vaccine developers such as
GlaxoSmithKline are making their licenced adjuvants
available for use with COVID-19 vaccines developed by
others [23, 33]. How far such cooperation will extend
into other areas of health and biomedical research is a
crucial question, but it is clear that conventions around
pharmaceutical intellectual property are being chal-
lenged in the COVID sphere [38]. There is increased at-
tention on OpenIP as well as the Medicines for Malaria
Venture, where intellectual property is retained but
drugs are accessible to users in poorer countries at af-
fordable prices [38]. Perhaps, going forward, there will
be more support for such approaches as a way to speed
up the development of interventions.
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Conclusions
It is claimed that, on average, it takes 17 years from
starting research to its translation into products, policies,
and practice [1] and the development of vaccines has
been reported to take on average over 10 years [23, 24].
To measure such time-lags and identify ways of reducing
them, in 2015, we published a matrix consisting of over-
lapping tracks in the translation from health research to
products, policies and practice. In the current pandemic,
it has proved useful to use the matrix to help interpret
the progress of the enormous global effort to develop a
vaccine against COVID-19, whilst also acknowledging
that some revision to our approach could be useful. For
example, the current situation highlights a fifth method
of accelerating translation – the development of tech-
nologies, such as vaccine platforms, that allow a range of
conditions to be rapidly addressed. It would be useful to
consider how far such approaches might contribute to
other areas.
Collectively, the vast global mobilisation is beginning
to adopt each of the approaches noted as potential ways
to reduce the time-lags. This is already being undertaken
in the early overlapping tracks in the matrix, i.e. through
the discovery (or basic) research and into the trial phases
of human research. Additionally, there are already indi-
cations of how the approaches would be taken into the
further overlapping tracks of human research and on to
rapid decisions by regulatory and reimbursement bodies
and, finally, into mainstream clinical practice. Reducing
the time taken from the start of the research to its trans-
lation from the previous noted average of 17 years to
anything like 17 months would be an astonishing
achievement but not without costs.
If something went wrong with the vaccine used, then,
as Jiang warned, there could be setbacks “into the future”
[30]. Provided, however, that all the speed results in one
or more safe and efficacious vaccines, there is a growing
opinion that the pandemic might make medical science
more nimble after the crisis has passed [22, 37] and re-
sult in greater preparedness in the future [21]. The situ-
ation is constantly evolving, with, for example, an update
in Nature in mid-May 2020 including an account from
Moderna that simultaneously reported the potentially
promising preliminary findings from the Phase I trial,
and an animal challenge study [39]. (This presentation
of dual data is consistent with the general agreement at
a virtual meeting of medicines regulatory authorities and
WHO that, while prior to Phase I trials for a COVID-19
vaccine it was necessary to obtain some animal data, it
was not always necessary to conduct animal challenge
studies [40]). It would be highly desirable for a team of
research analysts to monitor this unique situation pro-
spectively to inform future discussions about the scope
for realistically transferring lessons from the
development of the COVID-19 vaccine into wider les-
sons for accelerating the translation of early research
into health improvements.
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